Bottom line is that US investors understand, and have a much greater appetite for, bio stocks. If you are a L/T then IMO a listing in the US will deliver far greater value to shareholders, assuming of course that clinical trials are successful. Who knows in the S/T.
nasdaq listing, page-3
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.005(1.47%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 32.5¢ | $659.6K | 1.969M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 399004 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 4457 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |